Brand name:
INQOVI
INQOVI® for adult patients with MDS or CMML who are intermediate-1, intermediate-2, and high-risk IPSS groups. It is a prescribed oral tablet combination of decitabine and cedazurine approved by the FDA for adult patients with myelodysplastic syndromes (MDS) and patients with chronic myelomonocytic leukemia (CMML) including:
- previously treated and untreated, de novo and secondary MDS including the following subtypes (refractory anemia, refractory anemia with ringed sideroblasts, fractory anemia and excess blasts and CMML) and,
- intermediate-1, intermediate-2, and high risk IPSS groups.